Tirzepatide for weight and behavior management in a patient with Smith-Magenis syndrome
JCEM Case Reports · 20.05.2026 · 4 (7)
DOI: 10.1210/jcemcr/luag152 ↗Kurz gefasst
Fallbericht in der Zeitschrift JCEM Case Reports, online erschienen am 03.06.2026. Verfasst von X Charlene Liao und 3 weiteren Autor:innen. Beteiligte Einrichtung: Independent Scholar, Palo Alto, CA 94303, USA. Die Arbeit nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Smith–Magenis syndrome (SMS) is a rare neurodevelopmental disorder characterized by intellectual disability, behavioral dysregulation, and hyperphagia-driven obesity. While dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonists have demonstrated efficacy in the general population, their use in patients with SMS has not been described. We report the case of a 31-year-old woman with SMS (17p11.2 deletion) treated with tirzepatide, a dual GIP/GLP-1 receptor agonist. The patient presented with lifelong obesity (body mass index [BMI] 32.0-32.9 kg/m2 in adulthood) and aggressive behaviors refractory to standard management. Following initiation of tirzepatide, titrated to 5 mg weekly, she achieved 9.4% weight loss (7.3 kg) over 10 months, along with improvement in fasting glucose levels. Concurrently, caregivers reported notable behavioral improvements, including reduced food-seeking behavior and impulsivity. Quantitative analysis demonstrated a significant reduction in aggression. The treatment was well tolerated. This case suggests that tirzepatide may represent a promising therapeutic option for SMS, targeting both metabolic and central nervous system pathways involved in its phenotype.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Independent Scholar, Palo Alto, CA 94303, USA.
- Independent Scholar, Mountain View, CA 94041, USA.
- Department of Psychiatry and Behavioral Sciences, Stanford University, Stanford, CA 94305, USA.
- Howard Hughes Medical Institute, Department of Biology, Stanford University, Stanford, CA 94305, USA.
ORCID-Profile: X Charlene Liao, Tao Huang, David S Hong, Liqun Luo
Zitieren
APA
Liao, X. C., Huang, T., Hong, D. S., & Luo, L. (2026). Tirzepatide for weight and behavior management in a patient with Smith-Magenis syndrome. JCEM Case Reports, 4(7). https://doi.org/10.1210/jcemcr/luag152
Vancouver
Liao XC, Huang T, Hong DS, Luo L. Tirzepatide for weight and behavior management in a patient with Smith-Magenis syndrome. JCEM Case Reports. 2026;4(7). doi:10.1210/jcemcr/luag152
BibTeX
@article{Liao2026,
author = {Liao, X Charlene and Huang, Tao and Hong, David S and Luo, Liqun},
title = {Tirzepatide for weight and behavior management in a patient with Smith-Magenis syndrome},
journal = {JCEM Case Reports},
year = {2026},
volume = {4},
number = {7},
doi = {10.1210/jcemcr/luag152}
}
EUVIMED